Latest Close
$9.84
Stock Hub
CRBP
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$4.17 (+73.54%)
Market Cap
$174,526,816.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$5.12 to $20.56
Target Mean Price
$42.22
Beta
2.79
Trailing P/E
Not available
Forward P/E
-2.01
Price / Book
1.17
Company Overview
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.